Phase 0 1 trial
Phase 0
NCT03911453 Apr 2019 → Jul 2021 breast cancer University of Arizona
Completed
No outcome recorded
Phase 1 12 trials
Phase 1
NCT04179396 Dec 2019 → Nov 2021 castration-resistant prostate carcinoma pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT03840200 Jun 2019 → Dec 2021 breast cancer , ovarian cancer , prostate cancer Hoffmann-La Roche
Completed
No outcome recorded
Phase 1
NCT03954366 Apr → Dec 2019 neoplasm pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT03552471 Jul 2018 → Jun 2022 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , carcinosarcoma of the corpus uteri , endometrial serous adenocarcinoma +3 Ohio State University Comprehensive Cancer Center
Completed
No outcome recorded
Phase 1
NCT03542175 May 2018 → Jul 2024 breast cancer Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 1
NCT03521037 Feb 2018 → Sep 2019 neoplasm pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT03499444 Feb 2018 → Jun 2019 neoplasm pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT03318445 Jan 2018 → Mar 2021 cancer Pamela Munster
Completed
No outcome recorded
Phase 1
NCT03101280 Apr 2017 → Aug 2020 female reproductive system neoplasm Hoffmann-La Roche
Completed
No outcome recorded
Phase 1
NCT02986100 Nov 2016 → Dec 2017 neoplasm pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT02740712 Apr 2016 → Mar 2017 neoplasm pharmaand GmbH
Completed
No outcome recorded
Phase 1
NCT01009190 Feb 2010 → Apr 2014 cancer pharmaand GmbH
Completed
No outcome recorded
Show 2 more trials Phase 1/2 9 trials
Phase 1/2
NCT03462212 Mar 2021 → Mar 2025 female reproductive organ cancer Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Unknown
No outcome recorded
Phase 1/2
NCT04209595 Apr 2020 → Aug 2021 small cell lung carcinoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT04253262 Apr 2020 → Jan 2027 expected prostate carcinoma Brown University
Active not recruiting
No outcome recorded
Phase 1/2
NCT03995017 Jan 2020 → Oct 2022 esophageal adenocarcinoma , gastric adenocarcinoma University of Kansas Medical Center
Unknown
No outcome recorded
Phase 1/2
NCT03992131 Jun 2019 → Mar 2022 ovarian cancer , triple-negative breast carcinoma , urothelial carcinoma pharmaand GmbH
Terminated
No outcome recorded
Phase 1/2
NCT03559049 Dec 2018 → May 2025 non-small cell lung carcinoma University of Michigan Rogel Cancer Center
Terminated
No outcome recorded
Stop: Business
Phase 1/2
NCT03337087 Nov 2018 → Mar 2021 biliary tract cancer , colorectal carcinoma , gastroesophageal junction adenocarcinoma , pancreatic adenocarcinoma Academic and Community Cancer Research United
Unknown
No outcome recorded
Phase 1/2
NCT03572478 Aug 2018 → Feb 2020 endometrial cancer , prostate cancer University of Chicago
Terminated
No outcome recorded
Phase 1/2
NCT01482715 Nov 2011 → Mar 2019 fallopian tube cancer , ovarian cancer , peritoneum cancer pharmaand GmbH
Completed
No outcome recorded
Phase 2 28 trials · 2 met primary · 1 missed
Phase 2
NCT04624178 Nov 2020 → Nov 2025 overdue leiomyosarcoma Memorial Sloan Kettering Cancer Center
Active not recruiting
No outcome recorded
Phase 2
NCT04171700 Jan 2020 → Jun 2022 neoplasm pharmaand GmbH
Terminated
No outcome recorded
Phase 2
NCT03795272 Oct 2019 cervical cancer Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Withdrawn
No outcome recorded
Stop: Business
Phase 2
NCT03958045 Sep 2019 → Nov 2022 small cell lung carcinoma Zhonglin Hao
Completed
No outcome recorded
Phase 2
NCT03824704 Aug 2019 → Aug 2020 endometrioid adenocarcinoma , fallopian tube carcinoma , ovarian neoplasm , primary peritoneal carcinoma +1 pharmaand GmbH
Terminated
No outcome recorded
Stop: Enrollment
Phase 2
NCT03899155 Aug 2019 → Aug 2029 expected cancer Bristol-Myers Squibb
Recruiting
No outcome recorded
Phase 2
NCT03694262 Jul 2019 → Mar 2023 endometrial cancer , uterine carcinosarcoma Medical College of Wisconsin
Completed
No outcome recorded
Phase 2
NCT03533946 May 2019 → Jan 2023 prostate cancer University of Utah
Terminated
No outcome recorded
Phase 2
NCT03845296 Apr 2019 → Jan 2022 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , lung adenocarcinoma , lung large cell carcinoma +1 SWOG Cancer Research Network
Completed
No outcome recorded
Phase 2
NCT04276376 Apr 2019 → Jan 2023 cancer Gustave Roussy, Cancer Campus, Grand Paris
Terminated
No outcome recorded
Phase 2
NCT03639935 Mar 2019 → Feb 2023 biliary tract cancer University of Michigan Rogel Cancer Center
Completed
No outcome recorded
Phase 2
NCT03654833 Jan 2019 → Oct 2023 malignant mesothelioma University of Leicester
Unknown
Met primary
Phase 2
NCT03413995 Sep 2018 → Nov 2023 metastatic prostate carcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed
Missed primary
Phase 2
NCT03442556 Aug 2018 → Jun 2025 ATM-related cancer predisposition , BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , metastatic prostate carcinoma +1 University of Washington
Terminated
No outcome recorded
Stop: Business
Phase 2
NCT03476798 Jun 2018 → May 2020 cervical cancer , endometrial cancer University of Oklahoma
Completed
No outcome recorded
Phase 2
NCT03397394 Jun 2018 → Dec 2019 renal pelvis carcinoma , ureter carcinoma , urethra cancer , urinary bladder carcinoma +1 pharmaand GmbH
Terminated
No outcome recorded
Stop: Enrollment
Phase 2
NCT03338790 Dec 2017 → Jan 2021 prostate cancer Bristol-Myers Squibb
Completed
No outcome recorded
Phase 2
NCT03140670 Sep 2017 → Oct 2020 malignant pancreatic neoplasm Abramson Cancer Center at Penn Medicine
Terminated
No outcome recorded
Stop: Business
Phase 2
NCT02952534 Feb 2017 → Jul 2021 castration-resistant prostate carcinoma pharmaand GmbH
Completed
No outcome recorded
Phase 2
NCT02935634 Nov 2016 → May 2022 gastric cancer Bristol-Myers Squibb
Completed
No outcome recorded
Phase 2
NCT02873962 Nov 2016 → Feb 2025 overdue fallopian tube carcinoma , ovarian carcinoma , peritoneal carcinoma Dana-Farber Cancer Institute
Active not recruiting
No outcome recorded
Phase 2
NCT02925234 Aug 2016 → Sep 2027 expected cancer The Netherlands Cancer Institute
Recruiting
Mixed
Phase 2
NCT02505048 Mar 2016 → Feb 2019 breast cancer UNICANCER
Completed
No outcome recorded
Phase 2
NCT02678182 Feb 2015 → Apr 2025 overdue esophageal adenocarcinoma , gastric adenocarcinoma , gastroesophageal junction adenocarcinoma Royal Marsden NHS Foundation Trust
Active not recruiting
No outcome recorded
Phase 2
NCT02042378 Apr 2014 → Apr 2016 pancreatic ductal adenocarcinoma pharmaand GmbH
Completed
No outcome recorded
Phase 2
NCT01891344 Oct 2013 → Nov 2019 fallopian tube cancer , malignant epithelial tumor of ovary , peritoneum cancer pharmaand GmbH
Completed
Met primary
Phase 2
NCT00664781 Dec 2007 → Jan 2015 BRCA1-related cancer predisposition , BRCA2-related cancer predisposition , breast cancer , ovarian cancer Cancer Research UK
Completed
No outcome recorded
Phase 2
NCT00457470 Jun 2007 → ? diabetes mellitus , diabetic retinopathy Pfizer
Withdrawn
No outcome recorded
Stop: Enrollment
Show 18 more trials Phase 3 8 trials · 3 met primary
Phase 3
NCT04455750 Oct 2021 → Mar 2027 expected castration-resistant prostate carcinoma , prostate adenocarcinoma Alliance for Clinical Trials in Oncology
Active not recruiting
No outcome recorded
Phase 3
NCT04676334 Mar 2021 → Mar 2023 castration-resistant prostate carcinoma , fallopian tube cancer , malignant epithelial tumor of ovary , peritoneum cancer pharmaand GmbH
Completed
No outcome recorded
Phase 3
NCT04227522 Jun 2020 → Dec 2023 fallopian tube cancer , ovarian cancer , primary peritoneal carcinoma North Eastern German Society of Gynaecological Oncology
Completed
No outcome recorded
Phase 3
NCT03768063 Feb 2019 → Jul 2028 expected cancer Hoffmann-La Roche
Active not recruiting
No outcome recorded
Phase 3
NCT03522246 May 2018 → May 2024 overdue fallopian tube cancer , malignant epithelial tumor of ovary , primary peritoneal carcinoma pharmaand GmbH
Active not recruiting
Mixed
Phase 3
NCT02975934 Jun 2017 → Aug 2022 castration-resistant prostate carcinoma pharmaand GmbH
Completed
Met primary
Phase 3
NCT02855944 Mar 2017 → Dec 2020 fallopian tube cancer , malignant epithelial tumor of ovary , peritoneum cancer pharmaand GmbH
Completed
Met primary
Phase 3
NCT01968213 Apr 2014 → Apr 2017 fallopian tube cancer , ovarian cancer , peritoneum cancer pharmaand GmbH
Completed
Met primary
Comparator or background therapy 4 trials
Phase 1/2
NCT04826198 Background Oct 2020 → Apr 2024 ovarian cancer Gustave Roussy, Cancer Campus, Grand Paris
Terminated
No outcome recorded
Phase 1/2
NCT02711137 Background May 2016 → Feb 2019 cancer Incyte Corporation
Terminated
No outcome recorded
Phase 2
NCT03617679 Comparator Mar 2019 → Oct 2023 endometrial cancer University of Colorado, Denver
Completed
No outcome recorded
Phase 2
NCT01074970 Comparator Feb 2010 → Dec 2018 breast cancer Hoosier Cancer Research Network
Completed
No outcome recorded